{"drugs":["Cancidas","Caspofungin Acetate"],"mono":{"0":{"id":"926097-s-0","title":"Generic Names","mono":"Caspofungin Acetate"},"1":{"id":"926097-s-1","title":"Dosing and Indications","sub":[{"id":"926097-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Aspergillosis, Invasive, salvage therapy:<\/b> 70 mg IV infusion on day 1, followed by 50 mg IV daily thereafter; duration of therapy depends upon severity of patient's underlying disease, recovery from immunosuppression, and clinical response<\/li><li><b>Aspergillosis, Invasive - HIV infection:<\/b> 70 mg IV on day 1, followed by 50 mg IV daily; treat until the peripheral blood CD4+ count is more than 200 cells\/microliter and clinical response is evident<\/li><li><b>Candida endophthalmitis:<\/b> (alternative therapy) 70 mg IV infusion on day 1, followed by 50 mg IV daily for at least 4 to 6 weeks<\/li><li><b>Candidemia:<\/b> (primary therapy) 70 mg IV infusion on day 1, then 50 mg IV once daily thereafter; duration of therapy depends upon clinical response and microbiological response; continue for a minimum of 14 days beyond the first negative culture<\/li><li><b>Candidiasis, Cardiovascular system infection:<\/b> 70 mg IV infusion on day 1, followed by 50 to 150 mg IV daily thereafter<\/li><li><b>Candidiasis, Osteoarticular infection:<\/b> (alternative therapy) 70 mg IV infusion on day 1, then 50 mg IV daily for at least 2 weeks, followed by fluconazole therapy<\/li><li><b>Candidiasis of the esophagus:<\/b> (alternative therapy) 70 mg IV infusion on day 1, followed by 50 mg IV daily for 14 to 21 days<\/li><li><b>Candidiasis of the esophagus:<\/b> 50 mg IV once daily for 7 to 14 days after symptom resolution (manufacturer dosing)<\/li><li><b>Candidiasis of the esophagus - HIV infection:<\/b> 50 mg IV once daily for 14 to 21 days (guideline dosing)  OR 7 to 14 days after symptom resolution (manufacturer dosing)<\/li><li><b>Disseminated candidiasis, Chemotherapy-induced neutropenia; Prophylaxis:<\/b> (alternative therapy) 70 mg IV infusion on day 1 of induction chemotherapy, followed by 50 mg IV daily thereafter for the duration of neutropenia<\/li><li><b>Disseminated candidiasis, chronic:<\/b> (alternative therapy) 70 mg IV infusion on day 1, then 50 mg IV daily for 1 to 2 weeks, followed by oral fluconazole therapy when clinically stable<\/li><li><b>Disseminated candidiasis, Intra-abdominal abscesses, peritonitis, or pleural space infections:<\/b> 70 mg IV infusion on day 1, then 50 mg IV once daily thereafter; duration of therapy depends upon clinical response and microbiological response; continue for a minimum of 14 days beyond last positive culture<\/li><li><b>Febrile neutropenia, Empiric antifungal therapy:<\/b> 70 mg IV infusion on day 1, then 50 mg IV once daily thereafter; duration of therapy depends upon clinical response with empirical therapy continued until resolution of neutropenia; patients with fungal infection should be treated for a minimum of 14 days and treatment should continue for at least 7 days after both neutropenia and clinical symptoms resolve; if there is inadequate response and if 50-mg dose is well tolerated, daily dose may be increased to 70 mg<\/li><li><b>HIV infection - Oropharyngeal candidiasis:<\/b> (fluconazole-refractory) 50 mg IV daily<\/li><li><b>Oropharyngeal candidiasis:<\/b> (alternative therapy) 70 mg IV infusion on day 1, followed by 50 mg IV daily thereafter<\/li><li><b>Pulmonary aspergillosis, Chronic (cavitary or necrotizing):<\/b> (salvage therapy) 70 mg IV infusion on day 1, followed by 50 mg IV daily thereafter<\/li><\/ul>"},{"id":"926097-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness in children under 3 months of age are not established<\/li><li><b>Aspergillosis, Invasive, salvage therapy:<\/b> (3 months and older) 70 mg\/m(2) IV infusion on day 1 (MAX, 70 mg\/dose), then 50 mg\/m(2) IV once daily thereafter (MAX, 70 mg\/dose); duration of therapy depends upon severity of patient's underlying disease, recovery from immunosuppression, and clinical response; if there is inadequate response and the 50-mg\/m(2) dose is well tolerated, daily dose may be increased to 70 mg\/m(2) (MAX, 70 mg\/dose) (manufacturer dosing)<\/li><li><b>Aspergillosis, Invasive, salvage therapy:<\/b> 50 mg\/m(2) IV daily (guideline dosing)<\/li><li><b>Candidemia:<\/b> (3 months and older) 70 mg\/m(2) IV infusion on day 1 (MAX: 70 mg\/dose), then 50 mg\/m(2) IV once daily thereafter (MAX: 70 mg\/dose); duration of therapy depends upon clinical response and microbiological response; continue for a minimum of 14 days beyond last positive culture; if there is inadequate response and the 50-mg\/m(2) dose is well tolerated, daily dose may be increased to 70 mg\/m(2) (MAX: 70 mg\/dose)<\/li><li><b>Candidiasis of the esophagus:<\/b> (3 months and older) 70 mg\/m(2) IV infusion on day 1 (MAX: 70 mg\/dose), then 50 mg\/m(2) IV once daily (MAX: 70 mg\/dose) for 7 to 14 days after symptom resolution; if there is inadequate response and the 50-mg\/m(2) dose is well tolerated, daily dose may be increased to 70 mg\/m(2) (MAX: 70 mg\/dose)<\/li><li><b>Disseminated candidiasis, Intra-abdominal abscesses, peritonitis, or pleural space infections:<\/b> 70 mg\/m(2) IV infusion on day 1 (MAX: 70 mg\/dose), then 50 mg\/m(2) IV once daily thereafter (MAX: 70 mg\/dose); duration of therapy depends upon clinical response and microbiological response; continue for a minimum of 14 days beyond last positive culture; if there is inadequate response and the 50-mg\/m(2) dose is well tolerated, daily dose may be increased to 70 mg\/m(2) (MAX: 70 mg\/dose)<\/li><li><b>Febrile neutropenia, Empiric antifungal therapy:<\/b> (3 months and older) 70 mg\/m(2) IV infusion on day 1 (MAX: 70 mg\/dose), then 50 mg\/m(2) IV once daily thereafter (MAX: 70 mg\/dose); duration of therapy depends upon clinical response with empirical therapy continued until resolution of neutropenia; patients with fungal infection should be treated for a minimum of 14 days and treatment should continue for at least 7 days after both neutropenia and clinical symptoms resolve; if there is inadequate response and the 50-mg\/m(2) dose is well tolerated, daily dose may be increased to 70 mg\/m(2) (MAX: 70 mg\/dose)<\/li><\/ul>"},{"id":"926097-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>(pediatric) coadministration with rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin:<\/b> 70 mg\/m(2) IV once daily (MAX: 70 mg) is recommended<\/li><li><b>(adults) coadministration with rifampin:<\/b> 70 mg IV once daily is recommended<\/li><li><b>(adults) coadministration with nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin:<\/b> may consider increase to 70 mg IV once daily<\/li><li><b>(adults) hepatic impairment:<\/b> moderate impairment (Child-Pugh score 7-9), a 70-mg IV loading dose should be given on day 1 when a loading dose is recommended, followed by 35 mg IV once daily; no data in patients with severe hepatic impairment<\/li><li><b>renal impairment:<\/b> no dosage adjustment necessary<\/li><li><b>hemodialysis:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"926097-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Aspergillosis, Invasive, salvage therapy<\/li><li>Candidemia<\/li><li>Candidiasis of the esophagus<\/li><li>Candidiasis of the esophagus - HIV infection<\/li><li>Disseminated candidiasis, Intra-abdominal abscesses, peritonitis, or pleural space infections<\/li><li>Febrile neutropenia, Empiric antifungal therapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Aspergillosis, Invasive, initial therapy<\/li><li>Aspergillosis, Invasive - HIV infection<\/li><li>Candida endophthalmitis<\/li><li>Candidiasis, Cardiovascular system infection<\/li><li>Candidiasis, Osteoarticular infection<\/li><li>Disseminated candidiasis, Chemotherapy-induced neutropenia; Prophylaxis<\/li><li>Disseminated candidiasis, chronic<\/li><li>HIV infection - Oropharyngeal candidiasis<\/li><li>Invasive fungal infection<\/li><li>Invasive fungal infection; Prophylaxis<\/li><li>Oropharyngeal candidiasis<\/li><li>Pulmonary aspergillosis, Chronic (cavitary or necrotizing)<\/li><\/ul>"}]},"3":{"id":"926097-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926097-s-3-9","title":"Contraindications","mono":"hypersensitivity (eg, anaphylaxis) to caspofungin acetate or to any component of the product <br\/>"},{"id":"926097-s-3-10","title":"Precautions","mono":"<ul><li>anaphylaxis has been reported; discontinue use if occurs<\/li><li>hepatic abnormalities, including abnormal liver function tests and isolated cases of dysfunction, hepatitis, or hepatic failure, have been reported; monitoring recommended<\/li><li>hepatic impairment; dose adjustment may be required<\/li><li>histamine-mediated adverse reactions (eg, rash, facial swelling, angioedema, pruritus, sensation of warmth, bronchospasm) have been reported; discontinuation may be necessary<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"926097-s-3-11","title":"Pregnancy Category","mono":"Caspofungin: C (FDA)<br\/>"},{"id":"926097-s-3-12","title":"Breast Feeding","mono":"Caspofungin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"926097-s-4","title":"Drug Interactions","sub":{"1":{"id":"926097-s-4-14","title":"Major","mono":"<ul><li>Cyclosporine (established)<\/li><li>Tacrolimus (probable)<\/li><\/ul>"},"2":{"id":"926097-s-4-15","title":"Moderate","mono":"<ul><li>Carbamazepine (probable)<\/li><li>Dexamethasone (probable)<\/li><li>Efavirenz (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Nevirapine (probable)<\/li><li>Phenytoin (probable)<\/li><li>Rifampin (established)<\/li><\/ul>"}}},"5":{"id":"926097-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (3% to 20%)<\/li><li><b>Dermatologic:<\/b>Rash (4% to 23%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (6% to 27%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (4% to 18%), AST\/SGOT level raised (2% to 17%), Serum alkaline phosphatase raised (9% to 22%)<\/li><li><b>Other:<\/b>Complication of infusion (20% to 35%), Fever (6% to 30%), Shivering (9% to 23%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Sepsis (up to 7%), Septic shock (11% to 14%)<\/li><li><b>Renal:<\/b>Nephrotoxicity, Renal impairment<\/li><li><b>Respiratory:<\/b>Pleural effusion (9%), Respiratory distress (up to 8%), Respiratory failure (2% to 20%)<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"926097-s-6","title":"Drug Name Info","sub":{"0":{"id":"926097-s-6-17","title":"US Trade Names","mono":"Cancidas<br\/>"},"2":{"id":"926097-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Echinocandin<\/li><li>Glucan Synthesis Inhibitor<\/li><\/ul>"},"3":{"id":"926097-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926097-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"926097-s-7","title":"Mechanism Of Action","mono":"Caspofungin acetate is an antifungal that inhibits beta (1,3)-D-glucan synthesis, an important component of the cell wall of susceptible organisms including Aspergillus and Candida species.<br\/>"},"8":{"id":"926097-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"926097-s-8-24","title":"Distribution","mono":"Protein binding: approximately 97% <br\/>"},"2":{"id":"926097-s-8-25","title":"Metabolism","mono":"<ul><li>spontaneous degradation, hydrolysis and N-acetylation<\/li><li>Metabolites: L-747969, dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine<\/li><\/ul>"},"3":{"id":"926097-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 35% as metabolites and unchanged drug<\/li><li>Renal: 41%, approximately 1.4% unchanged<\/li><li>Dialyzable: no<\/li><\/ul>"},"4":{"id":"926097-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adults: (intravenous, 50 mg\/d), 13 +\/- 1.9 h<\/li><li>Adults: (intravenous, 70 mg\/d), 16.5 +\/- 7 h<\/li><li>Adolescents (aged 12 to 17 years): (intravenous, 50 mg\/m(2)\/d), 11.2 +\/- 1.7 h<\/li><li>Children (aged 2 to 11 years): (intravenous, 50 mg\/m(2)\/d), 8.2 +\/- 2.4 h<\/li><li>Children (aged 2 to 11 years): (intravenous, 70 mg\/m(2)\/d), 9.7 +\/-2 h<\/li><\/ul>"}}},"9":{"id":"926097-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>do not mix with dextrose-containing solutions<\/li><li>reconstitute vial with 10.8 mL of NS, Sterile Water for Injection, or Bacteriostatic Water for Injection to a final concentration of 5 mg\/mL for the 50-mg vial and 7 mg\/mL for the 70-mg vial (vials contain overfill); reconstituted vials may be stored up to 1 hour at 25 degrees C (77 degrees F) or less; discard unused solution<\/li><li>(pediatric patients) reconstituted 50-mg vial (5 mg\/mL) should be used for doses less than 50 mg<\/li><li>dilute appropriate volume of reconstituted drug in 250 mL or less of NS, 0.45% sodium chloride, 0.225% sodium chloride, or LR; final concentration should not exceed 0.5 mg\/mL; diluted solution should be used within 24 hours when stored at 25 degrees C (77 degrees F) or less or within 48 hours when stored in the refrigerator at 2 to 8 degrees C (36 to 46 degrees F)<\/li><li>administer as a slow IV infusion over about 1 hour; do not administer as an IV bolus<\/li><\/ul>"},"10":{"id":"926097-s-10","title":"Monitoring","mono":"<ul><li>microbiologic clearance of Candida or Aspergillus infection<\/li><li>CBC with differential assessment, with normalization of neutrophil count<\/li><li>empirical therapy in febrile neutropenia; resolution of fever and signs and symptoms of fungal infection<\/li><li>candidiasis; improvement and\/or resolution of clinical signs and symptoms of fungal infection<\/li><li>invasive aspergillosis; improvement of computed tomography or other radiographic findings<\/li><li>liver function tests<\/li><\/ul>"},"11":{"id":"926097-s-11","title":"How Supplied","mono":"<b>Cancidas<\/b><br\/>Intravenous Powder for Solution: 50 MG, 70 MG<br\/>"},"13":{"id":"926097-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause nausea, vomiting, headache, or fever.<\/li><li>Instruct patients with history of hepatic impairment to report signs\/symptoms of hepatic dysfunction.<\/li><\/ul>"}}}